AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Description: Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.~Age ≥1 year, 375 mg/m\^2 IV over 15-30 minutes Age \<1 year, 187l.5 mg/m\^2 (i.e., a 50% dose reduction) IV over 15-30 minutes.
Study NCT01871766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ^1^1C-methionine
Description: Participants receive \^1\^1C-methionine to relate the distribution, intensity and change in \^1\^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
Study NCT04814316 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine specimens
Description: Blood and urine samples will be taken at baseline and at the end of the second month. For this purpose, 5 ml of blood samples will be taken to plain blood tubes for evaluation of calcium, magnesium, alkaline phosphatase, parathormone, 25-OH vitamin D and osteocalcin quantities. And 3 ml of urine for calcium, creatinine, deoxypyridinoline, C-terminal telopeptides type-1 collagen and N- terminal telopeptides type-1 collagen.
Study NCT03910530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Part 1: INCMGA00012 500 mg every 4 weeks administered intravenously over 60 minutes.
Study NCT03910530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB001158
Description: Part 1: INCB001158 75 or 100 mg twice daily administered orally.
Study NCT03910530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Retifanlimab + INCB001158
Description: Part 2: INCB001158 at the recommended Phase 2 dose selected from Part 1 in combination with INCMGA00012 .
Study NCT01537016 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PROMOGRAN
Description: PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen
Study NCT01537016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tielle
Description: Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
Study NCT01917344 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: MRI
Study NCT04040634 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intensive Control of Systolic Blood Pressure (SBP)
Description: Participants in the Intensive arm have a goal of SBP \<120 mm Hg. The use of angiotensin converting enzyme (ACE) inhibitors/angiotension receptor blockers (ARB), thiazide-type diuretics, and calcium channel blockers (CCB) will be encouraged, preferably fixed-dose combinations of indapamide + perindopril arginine, perindopril arginine + amlodipine or indapamide + perindopril arginine + amlodipine
Study NCT04040634 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard control of Systolic Blood Pressure (SBP)
Description: The same medications used in the Intensive BP arm will be used for the Standard BP arm.
Study NCT03141775 — intervention group
Intervention type: OTHER
Intervention: Treatment of CDI
Description: Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
Study NCT04445506 — intervention group
Intervention type: DRUG
Intervention: Dexamethasone
Description: 4mg dexamethasone was given to some patients three times daily for 2 days, 2 times daily for 2 days, once daily for 2 days.
Study NCT00955968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Highly active antiretroviral therapy (HAART)
Description: A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant.
Study NCT00955968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Highly active antiretroviral therapy (HAART)
Description: A combination of three or more HIV medications belonging to two or more drug classes.~The preferred study-supplied HAART regimen was lopinavir/ritonavir (LPV/RTV) plus fixed dose combination tenofovir/emtricitabine (TDF/FTC). Additional ARVs provided for use in this study included fixed dose combination lamivudine/zidovudine (3TC/ZDV), lamivudine (3TC), zidovudine (ZDV), tenofovir (TDF), fixed dose combination tenofovir/emtricitabine/rilpivirine (TDF/FTC/RPV), didanosine (ddI), atazanavir (ATV), raltegravir (RAL), and ritonavir (RTV). While LPV/RTV plus TDF/FTC was the preferred study-supplied regimen, the study clinicians in conjunction with participants would determine the optimal drug combination for each participant.
Study NCT03684551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The CHW-led health system
Description: During the study period, all CHWs, regardless of treatment arm, performed proactive case detection, the process of conducting at least two hours per day of door-to-door home visits to proactively identify - through health history inquiry and/or disease diagnostics - patients who need care. For all patients identified, CHWs provided doorstep counselling, evaluation, diagnostics, treatment, referral to appropriate health facilities, and follow-up. CHWs provided care in the community without user fees, and were able to refer patients to the reinforced government primary health centres for care without user fees as well. CHWs were residents of the communities they served, and they were required to be available at home or by phone for consultation at any time.
Study NCT03684551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The CHW-led health system
Description: During the study period, all CHWs, regardless of treatment arm, performed proactive case detection, the process of conducting at least two hours per day of door-to-door home visits to proactively identify - through health history inquiry and/or disease diagnostics - patients who need care. For all patients identified, CHWs provided doorstep counselling, evaluation, diagnostics, treatment, referral to appropriate health facilities, and follow-up. CHWs provided care in the community without user fees, and were able to refer patients to the reinforced government primary health centres for care without user fees as well. CHWs were residents of the communities they served, and they were required to be available at home or by phone for consultation at any time.
Study NCT03684551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The CHW Supervision model
Description: CHWs in both study arms received monthly individual supervisory sessions and weekly group supervisory sessions from their dedicated CHW supervisor. An individual monthly session of 360 Supervision included: (i) solicitation of patient perspectives of CHW care; (ii) direct observation of CHW doorstep care; and (iii) a one-on-one feedback discussion with or without the CHW Performance Dashboard depending on treatment arm.
Study NCT03684551 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The CHW Supervision model
Description: CHWs in both study arms received monthly individual supervisory sessions and weekly group supervisory sessions from their dedicated CHW supervisor. An individual monthly session of 360 Supervision included: (i) solicitation of patient perspectives of CHW care; (ii) direct observation of CHW doorstep care; and (iii) a one-on-one feedback discussion with or without the CHW Performance Dashboard depending on treatment arm.
Study NCT03684551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The CHW Performance Dashboard
Description: The CHW Performance Dashboard was a graphic display of a CHW's performance along three indicators defined as follows: (i) Quantity of care: the number of homes visited during the month; (ii) Timeliness of care: the percentage of sick children under five treated within 24 hours of symptom onset during the month; (iii) Quality of care: the percentage of sick children under five treated without protocol error among 23 potential errors during the month. The Dashboard displayed an individual CHW's quantity, timeliness, and quality of care indicators from the previous month, using absolute numbers, percentages, and visual graphics, alongside those of the highest performing CHW. During the individual supervisory feedback session, this personalised and relative (to the highest performer) quantitative performance feedback helped orient the discussion of strengths and weaknesses, and allowed the CHW to see quantitatively and visually how his/her performance fared the previous month.
Study NCT01764724 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mock package questionnaire
Description: Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
Study NCT01348113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Alcohol intervention
Description: Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
Study NCT00401544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darbepoetin alfa
Description: Darbepoetin alfa administered by subcutaneous injection.
Study NCT00401544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: Darbepoetin alfa administered by subcutaneous injection.
Study NCT00401544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV iron dextran
Description: Administered by intravenous (IV) injection.
Study NCT00401544 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV iron dextran
Description: Administered by intravenous (IV) injection.
Study NCT02300350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment A digoxin
Description: 0.5 mg digoxin administered on Day 1 and Day 20
Study NCT02300350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment B LX4211
Description: 400 mg LX4211 administered daily on Day 14 through Day 25
Study NCT02300350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment C Digoxin + 400 mg LX4211 administered concomitantly
Description: 0.5 mg Digoxin + 400 mg LX4211 administered concomitantly on Day 20
Study NCT04397471 — intervention group
Intervention type: PROCEDURE
Intervention: Bone Marrow Harvest
Description: Healthy volunteer bone marrow harvest
Study NCT02440321 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-child interactive program
Study NCT02440321 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: written materials
Study NCT01591551 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Natalizumab (Tysabri)
Description: 300 mg IV every 4 weeks
Study NCT04616105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN6490
Description: Single dose of REGN6490
Study NCT04616105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching single dose of REGN6490
Study NCT02680184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: CMP-001 will be administered as per the dose and schedule specified in the respective arms.
Study NCT02680184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as per the schedule specified in the respective arms.
Study NCT04603794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.5% Povidone Iodine
Description: Commercially Available Mouth Rinses and Over the Counter Standard Formulations
Study NCT04603794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.12% Chlorhexidine Gluconate Mouth Rinse
Description: Commercially Available Mouth Rinses
Study NCT04603794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1% Hydrogen Peroxide
Description: Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
Study NCT04603794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline
Description: Commercially Available Over the Counter Standard Formulations USP (United States Pharmacopeia)
Study NCT04164823 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical taping
Description: For the medical taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
Study NCT04164823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Analgesic self-medication (OTC)
Description: Participants will note the usual analgesic self-medication used to relief pain (ibuprofen, acetaminophen...).
Study NCT03404258 — intervention group
Intervention type: OTHER
Intervention: Research Blood Sampling
Description: Blood samples will be collected at specified time points and research assays will be performed.
Study NCT02611921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
Study NCT05581992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral Tablet
Study NCT05581992 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Capsule
Study NCT02035098 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the Pac-IFicO programme
Description: The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
Study NCT00733564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Paracervical injection of 2% Lidocaine to block associated nociception input
Study NCT00733564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
Study NCT02153229 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Study NCT02153229 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radical Pleurectomy
Study NCT02153229 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Study NCT02153229 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Photofrin 2.0 mg/kg
Description: If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
Study NCT04568525 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Passive Microwave Radiometry
Description: The MWR2020 (ormer RTM-01-RES) device is a unique commercially available CE marked device. It is registered in UK MHRA MDN 40802 as Microwave thermography system for clinical studies. The device is already registered in Kyrgyzstan for breast cancer diagnostics. During the 1980-90s there were several works on identification of excess of microwave emission due to fluid in lungs (on phantoms) which could be indication of inflammatory, process, cancer and other lung disorders.Later results were confirmed by clinical studies for lung cancer
Study NCT00733564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
Study NCT00038623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-ibritumomab (Zevalin)
Description: After Rituximab infusion, 111\^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
Study NCT00038623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 250 mg/m\^2 in the vein over 6 to 8 hours on Day 1.
Study NCT06402591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin
Description: cefazolin extended prophylaxis 5 days (15 doses)
Study NCT01291576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal/colorectal segmental resection
Description: Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis
Study NCT01291576 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectal nodule excision
Description: Either full thickness excision or rectal shaving
Study NCT05656703 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BIS guidance of anesthesia
Description: Anesthesia is to be directed to a specific (light) level by the dosage of administered hypnotics and analgesics
Study NCT05656703 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Anesthesia is administered as usual
Study NCT01992315 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adipose-derived ECM
Description: Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.
Study NCT04650906 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindhelper - a national youth mental health promotion website
Description: Mindhelper is a fully digital youth mental health service reaching out to a large number of young people when and where they need it, with full anonymity. Mindhelper was developed in 2014-2017 by Centre for Telepsychiatry in the Region of Southern Denmark in a partnership with four Danish municipalities. The development of the site was funded by the Danish foundation TrygFonden. The original idea behind the site was inspired by the Australian youth mental health promotion service ReachOut.com. The Mindhelper service was launched in September 2016. From January 2019 Mindhelper received permanent funding through a joint agreement between the five Danish Regions. Mindhelper is Denmark's most comprehensive youth mental health promotion website where young people can seek mental health information, advice, and self-help tools to improve their mental health and well-being. Since it was launched, the site has been very successful in attracting large numbers of visitors.
Study NCT02689882 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: nicotinamide riboside
Description: Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
Study NCT04824755 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Yune Zhao
Description: Yune Zhao did congenital cataract surgeries
Study NCT05290480 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: expiratory muscle training
Description: participants performed expiratory muscle training according to their maximum expiratory pressure that measured earlier in addition to conventional chest physiotherapy
Study NCT05290480 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insentive spirometry
Description: participants performed deep breating exercise with insentive spirometry in additional to convantional chest physiotherapy
Study NCT02903524 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride Liposome injection and cyclophosphamide
Study NCT02903524 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pirarubicin and cyclophosphamide
Study NCT02939716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rhubarb
Description: 300gm rhubarb
Study NCT02939716 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bread
Description: 2 slices bread
Study NCT02939716 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lettuce
Description: 300g lettuce
Study NCT02970019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: K0706
Description: Once a day administration after fast
Study NCT02970019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Once a day administration after fast